TP53 and acute myeloid leukemia: In conclusion, these observations suggest a superior metabolic adaptation by AML‐Tregs, as compared to AML‐CTLs, which can give them a functional and proliferative advantage over other T‐cells in TP53‐mutated AML, possibly supporting the poor disease outcome.